-
アレックス・ボディ、CRIFとともに透明性の高い投資と徹底した資金洗浄防止に注力
-
India releases 'cockroach' leaders as movement calls for more protests
-
Brennan holds off Schauffele for PGA Tour win in Japan
-
Ο ALEX BODI δίνει έμφαση, σε συνεργασία με την CRIF, στις διαφανείς επενδύσεις και στη συστηματική πρόληψη της νομιμοποίησης εσόδων από παράνομες δραστηριότητες
-
ALEX BODI satsar tillsammans med CRIF på transparenta investeringar och ett konsekvent arbete mot penningtvätt
-
ALEX BODI sází ve spolupráci s CRIF na transparentní investice a důslednou prevenci praní špinavých peněz
-
ALEX BODI stawia wraz z CRIF na przejrzyste inwestycje i konsekwentne przeciwdziałanie praniu pieniędzy
-
एलेक्स बोदी क्रिफ के सहयोग से पारदर्शी निवेश और धनशोधन की कड़ाई से रोकथाम पर ज़ोर देते हैं
-
알렉스 보디, CRIF와 함께 투명한 투자와 철저한 자금세탁방지에 주력
-
ALEX BODI 攜手 CRIF,推動透明投資並貫徹洗錢防制
-
ALEX BODI turns to CRIF for transparent investment and rigorous money laundering prevention
-
Indian court releases 'cockroach' movement leaders from detention
-
The 'cockroach' protests against India's election body
-
Indonesia releases eight orangutans rescued from fires to protected forest
-
Power, water, jobs: Google on India data centre concerns
-
Russian Yandex data centre operations disrupted after drone strike
-
Google faces backlash against India data centre
-
Architect fights to save India's past, built on 'stone, tears and sweat'
-
Trump urges Zelensky replacement as diesel row rages
-
Hurricane Simon strengthens as it nears western Mexico
-
New Yorkers snap up discarded subway signs, seats at annual sale
-
'Everyone is angry': Okinawans fearful and frustrated after killing
-
Messi nets brace to win in first match after Argentina exit
-
Trump's trade wars sting US manufacturers ahead of midterms
-
Ravindra fit for New Zealand ODI series against India
-
Kenyan great Kipchoge wins first marathon in three years
-
All Blacks lose four players for second Wallabies Test
-
Barca extend perfect streak, Real Madrid survive Vinicius red
-
Spanish women return to action with 2-0 friendly win over USA
-
PSG ease to Ligue 1 win before Manchester City test
-
Bordeaux-Begles end wait for away win before Champions Cup defence
-
Real Madrid edge Villarreal, Vinicius sent off for hair pull
-
Traumatized Panamanians begin quake recovery
-
Carrick demands more 'streetwise' Man Utd after Spurs setback
-
Palestinian Mahmoud Abu Hamda wins top photography prize at Bayeux
-
10-man Tottenham ramp up pressure on Man Utd boss Carrick
-
Inter Milan dominate Parma to go top of Serie A
-
India 'cockroach' movement says thousands detained in Delhi protest
-
Barca extend perfect streak, Atletico scrape late win
-
Injury ends season for NHL Rangers star goalie Shesterkin
-
10-man Tottenham strike back to hold Man Utd
-
Ten-man Spurs rescue draw at Man Utd, Arsenal survive Leeds scare
-
Gordon nets first Barca goal as Liga leaders beat Getafe
-
Inter Milan dominate Parma to go top in Serie A
-
Trump, Zelensky clash over diesel deal as Russian strikes kill 21
-
Abbas postpones Palestinian legislative elections to September 2027
-
Thousands join pro-Palestinian marches in several European cities
-
'I don't feel fear': Fulham boss Arbeloa hits back as pressure mounts
-
Sleightholme scores hat-trick as Northampton overwhelm Bath in 18-try clash
-
Hurricane Simon strengthens to category 4 as it nears western Mexico
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Anderson--AT